Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 10/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16004606 | 0.86 | GRM5 (0.57) | GRM5KCNH2CYP1A2 | |
| SCHEMBL30526535 | 0.86 | GRM5 (0.57) | GRM5KCNH2CYP1A2 | |
| SCHEMBL22809928 | 0.83 | GRM5 (0.57) | GRM5KCNH2CYP1A2 | |
| Methyl Alcohol SCHEMBL28902013 | 0.81 | GRM5 (0.67) | GRM5KCNH2CYP1A2 | |
| SCHEMBL352291 | 0.81 | GRM5 (0.65) | GRM5KCNH2CYP1A2 | |
| SCHEMBL3416733 | 0.78 | KIT (0.53) | GRM5 | |
| SCHEMBL3644208 | 0.78 | TSHR (0.62) | GRM5CYP1A2TSHR | |
| SCHEMBL30666154 | 0.78 | TSHR (0.62) | GRM5CYP1A2TSHR | |
| SCHEMBL12424795 | 0.77 | GRM5 (0.55) | GRM5KCNH2CYP1A2 | |
| SCHEMBL1921319 | 0.77 | GRM5 (0.57) | GRM5KCNH2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108794385-B | Method for synthesizing phenylethynyl pyridine derivative | 陕西师范大学 | 2021-09-21 | — | — | CN | disclosed |
| CN-108794385-A | A method of synthesis phenylethynylpyridin derivative | 陕西师范大学 | 2018-11-13 | — | — | CN | disclosed |
| EP-2473166-A2 | TREATMENT AND PREVENTION OF SECONDARY INJURY AFTER TRAUMA OR DAMAGE TO THE CENTRAL NERVOUS SYSTEM | Schneider, Eric B. (US) | 2012-07-11 | — | — | EP | disclosed |
| US-20120157420-A1 | TREATMENT AND PREVENTION OF SECONDARY INJURY AFTER TRAUMA OR DAMAGE TO THE CENTRAL NERVOUS SYSTEM | SCHNEIDER ERIC B (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011026060-A2 | TREATMENT AND PREVENTION OF SECONDARY INJURY AFTER TRAUMA OR DAMAGE TO THE CENTRAL NERVOUS SYSTEM | SCHNEIDER ERIC B (US) | 2011-03-03 | — | — | WO | disclosed |
| US-20100234402-A1 | METHODS AND COMPOSITIONS FOR TREATING SPINAL MUSCULAR ATROPHY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2010-09-16 | — | — | US | disclosed |
| WO-2009016486-A2 | USE OF NMDA RECEPTOR ANTAGONISTS FOR TREATMENT OF UROLOGIC TUMORS | COMPUGEN, LTD (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008150509-A1 | METHODS AND COMPOSITIONS FOR TREATING SPINAL MUSCULAR ATROPHY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20060286167-A1 | Compositions and methods for the treatment of neurodegenerative diseases | STAUNTON JANE | 2006-12-21 | — | — | US | disclosed |
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | COMBINATORX, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006119329-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | COMBINATORX, INCORPORATED (US) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006119295-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | COMBINATORX, INCORPORATED (US) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | PSEN2, PSEN1, HTT | GRM5 269/4885KCNH2 1567/4885CYP1A2 4301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.